Endo Therapeutics' late-stage trial for Rapinyl, a cancer pain therapy, demonstrated that the therapy was highly effective, hitting all primary and secondary goals. The biotech said the trial was so successful--relieving cancer pain for a statistically significant group within 30 minutes--that it may go ahead with an application for marketing approval even as it recruits patients for another Phase III trial. The side effects of the drug were in line with other opioids. That's all good news for Orexo AB, which licensed the therapy to Endo.
"We remain confident that Rapinyl's quick dissolution and rapid absorption profile make it a potentially attractive treatment for breakthrough cancer pain," said David A. Lee, M.D., Ph.D., the company's CSO.
- check out the release for more info
Endo plans for the future. Report
Endo, Vernalis get FDA rejection for Frova. Report
Endo shares up on positive painkiller data. Report